No Data
No Data
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Announces Target Price $17
Sector Update: Health Care Stocks Advance Pre-Bell Thursday
Sector Update: Health Care
Top Premarket Gainers
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
The ClearPoint Neuro, Inc. (NASDAQ:CLPT) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
No Data
No Data